Abstract
Objective: To examine the clinical and histological outcomes following intra-articular injection of an immunomodulatory peptide (CP) during an acute attack of adjuvant induced arthritis in rats. Methods: Arthritis in rats was induced by injecting 0.1mL of Mycobacterium Tuberculosis (MTB; 10mg/ml) intra-dermally at the base of the tail. After the onset of arthritis, affected ankle joints were injected with either 20μl of water, dexamethasone (4mg/ml), cyclosporine (0.38mg; equivalent to 3mg/kg in humans), CP (60mg/ml; 12.5 mg/ml; 6.25 mg/ml; 3.125 mg/ml) or a CP analogue (CPD; 6.25mg/ml). There were a minimum of 5 rats/group and intra-articular injection was given on two separate occasions following the onset of arthritis. Rat weight, paw thickness, paw-width, ankle width and arthritic joint count were measured. Affected joints were X-rayed and joint tissue taken for histology. Results: Rats given dexamethasone and cyclosporine had a significant improvement in clinical outcomes compared to the control group. CP at the highest dose was significantly better compared to the water group and the clinical effects were dose dependent. Histology of the joints showed severe inflammation and destruction in the water treated group with minimal inflammatory effects in the dexamethasone and cyclosporine group. Joints injected with cyclosporine were characterized by extensive fibrosis. The joints from CP treated rats showed mild to moderate inflammation with histological features somewhere between the cyclosporine and water injected groups. Conclusion: This study demonstrates that CP given intra-articularly has antiarthritic effects and raises new possibilities for treatment.
Keywords: Inflammation, animal model, adjuvant induced arthritis, peptides, therapeutics, intra-articular injection, Arthritis, core peptide, drug delivery
Current Drug Delivery
Title: Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints
Volume: 8 Issue: 6
Author(s): Yun Lu, Raghwa Sharma, Marina Ali, Karen Byth and Nicholas Manolios
Affiliation:
Keywords: Inflammation, animal model, adjuvant induced arthritis, peptides, therapeutics, intra-articular injection, Arthritis, core peptide, drug delivery
Abstract: Objective: To examine the clinical and histological outcomes following intra-articular injection of an immunomodulatory peptide (CP) during an acute attack of adjuvant induced arthritis in rats. Methods: Arthritis in rats was induced by injecting 0.1mL of Mycobacterium Tuberculosis (MTB; 10mg/ml) intra-dermally at the base of the tail. After the onset of arthritis, affected ankle joints were injected with either 20μl of water, dexamethasone (4mg/ml), cyclosporine (0.38mg; equivalent to 3mg/kg in humans), CP (60mg/ml; 12.5 mg/ml; 6.25 mg/ml; 3.125 mg/ml) or a CP analogue (CPD; 6.25mg/ml). There were a minimum of 5 rats/group and intra-articular injection was given on two separate occasions following the onset of arthritis. Rat weight, paw thickness, paw-width, ankle width and arthritic joint count were measured. Affected joints were X-rayed and joint tissue taken for histology. Results: Rats given dexamethasone and cyclosporine had a significant improvement in clinical outcomes compared to the control group. CP at the highest dose was significantly better compared to the water group and the clinical effects were dose dependent. Histology of the joints showed severe inflammation and destruction in the water treated group with minimal inflammatory effects in the dexamethasone and cyclosporine group. Joints injected with cyclosporine were characterized by extensive fibrosis. The joints from CP treated rats showed mild to moderate inflammation with histological features somewhere between the cyclosporine and water injected groups. Conclusion: This study demonstrates that CP given intra-articularly has antiarthritic effects and raises new possibilities for treatment.
Export Options
About this article
Cite this article as:
Lu Yun, Sharma Raghwa, Ali Marina, Byth Karen and Manolios Nicholas, Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints, Current Drug Delivery 2011; 8 (6) . https://dx.doi.org/10.2174/156720111797635478
DOI https://dx.doi.org/10.2174/156720111797635478 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin-D in the Immune System: Genomic and Non-Genomic Actions
Mini-Reviews in Medicinal Chemistry Prediction of Small Molecules Metabolic Pathways Based on Functional Group Composition
Protein & Peptide Letters Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design A New Battlefield Towards Global Health in 21<sup>st</sup> Century: Clinical Research Networks
Applied Clinical Research, Clinical Trials and Regulatory Affairs Developments in Chemical Approaches to Treat Tuberculosis in the Last Decade
Current Medicinal Chemistry QSAR and the Prediction of T-Cell Epitopes
Current Proteomics Predicting the Impact of Antiretrovirals in Resource-Poor Settings: Preventing HIV Infections whilst Controlling Drug Resistance
Current Drug Targets - Infectious Disorders The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Functionally Engineered Nanosized Particles in Pharmaceutics: Improved Oral Delivery of Poorly Water-soluble Drugs
Current Pharmaceutical Design Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Psoriatic Arthritis – Review of the Immunologic, Clinic and Therapeutic Aspects of an Inflammatory Systemic Disease
Current Rheumatology Reviews Large Disclosing the Nature of Computational Tools for the Analysis of Next Generation Sequencing Data
Current Topics in Medicinal Chemistry Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs
Current Pharmaceutical Design The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis
Current Pharmaceutical Biotechnology Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism Patent Selections:
Recent Patents on Anti-Infective Drug Discovery